The frequency of medical reversals in a cross-sectional analysis of high-impact oncology journals, 2009–2018
Autor: | Emerson Y. Chen, Vinay Prasad, Talal Hilal, Myung S. Kim, Jennifer Gill, Tyler Crain, Alyson Haslam, Diana Herrera-Perez |
---|---|
Rok vydání: | 2021 |
Předmět: |
Oncology
Cancer Research medicine.medical_specialty Cross-sectional study Medical Oncology 03 medical and health sciences 0302 clinical medicine Surgical oncology Internal medicine Intervention Type Genetics medicine Humans RC254-282 030304 developmental biology Medical reversal 0303 health sciences business.industry Research Publications Neoplasms. Tumors. Oncology. Including cancer and carcinogens Low-value care Cross-Sectional Studies 030220 oncology & carcinogenesis Periodicals as Topic business |
Zdroj: | BMC Cancer, Vol 21, Iss 1, Pp 1-9 (2021) BMC Cancer |
ISSN: | 1471-2407 |
Popis: | Background Identifying ineffective practices that have been used in oncology is important in reducing wasted resources and harm. We sought to examine the prevalence of practices that are being used but have been shown in RCTs to be ineffective (medical reversals) in published oncology studies. Methods We cross-sectionally analyzed studies published in three high-impact oncology medical journals (2009–2018). We abstracted data relating to the frequency and characterization of medical reversals. Results Of the 64 oncology reversals, medications (44%) represented the most common intervention type (39% were targeted). Fourteen (22%) were funded by pharmaceutical/industry only and 56% were funded by an organization other than pharmaceutical/industry. The median number of years that the practice had been in use prior to the reversal study was 9 years (range 1–50 years). Conclusion Here we show that oncology reversals most often involve the administration of medications, have been practiced for years, and are often identified through studies funded by non-industry organizations. |
Databáze: | OpenAIRE |
Externí odkaz: |